Janssen Presents First-Ever Results from Dual Bispecific Com

/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the first-ever results from the Phase 1b RedirecTT-1 study of...

Related Keywords

United States , Israel , Chicago , Illinois , American , Christie Corbett , Arnob Banerjee , Yael Cohen , Satu Glawe , Early Development Oncology , Companies Of Johnson , Janssen Pharmaceutical Companies Of Johnson , National Comprehensive Cancer Network , None Of The Janssen Pharmaceutical Companies , American Society Of Clinical Oncology , Janssen Biotech Inc , National Cancer Institute , American Cancer Society , Johnson , Janssen Research Development , Exchange Commission , Other Administration Reactions , Aviv Sourasky Medical Center , Janssen Pharmaceutical Companies , European Commission , Hematology Institute , European Medicines Agency , Clinical Oncology , Annual Meeting , Myeloma Unit , Tel Aviv Sourasky Medical Center , Confidence Interval , Not Estimable , Global Medical Head , Janssen Research , Drug Administration , National Comprehensive Cancer , Orphan Drug Designation , Breakthrough Therapy Designation , Biologics License Application , Risk Evaluation , Mitigation Strategy , Release Syndrome , Fetal Toxicity , Prescribing Information , Boxed Warning , Pharmaceutical Companies , Infectious Diseases , Private Securities Litigation Reform Act , Annual Report , Note Regarding Forward Looking , Quarterly Reports , Results From , With Teclistamab , Simultaneously Targeting , Refractory Multiple Myeloma , American Society , Participants With Relapsed , Refractory Multiple , Janssen Biotech , European Medicines , Accessed June , Clinical Practice Guidelines , Comprehensive Cancer , Natl Acad Sci United , Plasma Cell , Accessed September , Statistics About Multiple Myeloma , Janssen Oncology ,